The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer

Affiliations

Editorial

Celestia S Higano. J Urol. 2017 May.

. 2017 May;197(5):1184-1186.

doi: 10.1016/j.juro.2017.02.065. Epub 2017 Feb 21.

¹ Departments of Medicine and Urology, University of Washington, Seattle, Washington.

No abstract available

Comment on

Intermittent endocrine therapy for advanced prostate cancer.
Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Klotz LH, et al. Cancer. 1986 Dec 1;58(11):2546-50. doi: 10.1002/1097-0142(19861201)58:11<2546::aid-cncr2820581131>3.0.co;2-n. Cancer. 1986. PMID: 2429759
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL. Tsai HT, et al. J Urol. 2017 May;197(5):1251-1257. doi: 10.1016/j.juro.2016.12.022. Epub 2016 Dec 16. J Urol. 2017. PMID: 27993663 Free PMC article.